secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2026-08-06T11:35:24+00:00
Accession:  0001520138-26-000312
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie Phase 2 SUNRISE-PD trial of bezisterim shows statistically significant improvements vs placebo
--------------------------------------------------------------------------------

- Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).
- Bezisterim improved biomarkers of neuroinflammation and systemic inflammation; composite neuroinflammation measure p=0.0018.
- 283 of 380 proteins shifted toward lower inflammatory burden (binomial p=3.2e-22).
- Bezisterim well-tolerated; adverse events 39.3% vs 51.7% placebo, no severe/serious AEs.
- Conference call scheduled for Aug 12, 2026 to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/0001520138-26-000312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/bivi-20260806_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-26-000312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer